MX359399B - Inhibidores de 17alfa-hidroxilasa/c17-20-liasa. - Google Patents
Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.Info
- Publication number
- MX359399B MX359399B MX2013012577A MX2013012577A MX359399B MX 359399 B MX359399 B MX 359399B MX 2013012577 A MX2013012577 A MX 2013012577A MX 2013012577 A MX2013012577 A MX 2013012577A MX 359399 B MX359399 B MX 359399B
- Authority
- MX
- Mexico
- Prior art keywords
- hydroxylase
- lyase inhibitors
- present
- lyase
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
La presente invención proporciona compuestos de la fórmula (I) (Ver Formula) o una sal farmacéuticamente aceptable de los mismos, en donde R1, R2, R3, R4, R5 y R6 son como se definen en la presente. Se ha encontrado que los compuestos de la presente invención son útiles como inhibidores de la l7a-hidroxilasa/C17-20 -liasa.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1256DE2011 | 2011-04-28 | ||
PCT/US2012/035583 WO2012149413A1 (en) | 2011-04-28 | 2012-04-27 | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013012577A MX2013012577A (es) | 2014-02-27 |
MX359399B true MX359399B (es) | 2018-09-27 |
Family
ID=46025984
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013012577A MX359399B (es) | 2011-04-28 | 2012-04-27 | Inhibidores de 17alfa-hidroxilasa/c17-20-liasa. |
Country Status (12)
Country | Link |
---|---|
US (2) | US9029399B2 (es) |
EP (1) | EP2702052B1 (es) |
JP (1) | JP6002210B2 (es) |
KR (1) | KR20140025492A (es) |
CN (1) | CN103649073B (es) |
AU (1) | AU2012249421B9 (es) |
BR (1) | BR112013027395A2 (es) |
CA (1) | CA2834224A1 (es) |
EA (1) | EA023064B1 (es) |
ES (1) | ES2656218T3 (es) |
MX (1) | MX359399B (es) |
WO (1) | WO2012149413A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2656218T3 (es) | 2011-04-28 | 2018-02-26 | Novartis Ag | Inhibidores de 17 alfa-hidroxilasa/C17,20-liasa |
WO2014194519A1 (en) * | 2013-06-07 | 2014-12-11 | Merck Sharp & Dohme Corp. | Imidazole derivatives and methods of use thereof for improving pharmacokinetics of drug |
US9981928B2 (en) | 2013-06-20 | 2018-05-29 | Bayer Cropscience Aktiengesellschaft | Aryl sulfide derivatives and aryl sulfoxide derivatives as acaricides and insecticides |
WO2015127548A1 (en) * | 2014-02-28 | 2015-09-03 | The Royal Institution For The Advancement Of Learning / Mcgill University | Tc-ptp inhibitors as apc activators for immunotherapy |
WO2019180631A1 (en) * | 2018-03-22 | 2019-09-26 | Aurigene Discovery Technologies Limited | Substituted imidazolidin-2-one derivatives as prmt5 inhibitors |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL39283A (en) | 1971-05-03 | 1976-01-30 | Ciba Geigy Ag | Substituted 2-oxo or thioxo-3-(5-nitro-imidazol-2-yl)-tetrahydroimidazoles and their manufacture |
GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
LU88769I2 (fr) | 1982-07-23 | 1996-11-05 | Zeneca Ltd | Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R)) |
GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
CA1326234C (en) | 1987-04-22 | 1994-01-18 | Michael R. Angelastro | 17.beta.-(cyclopropylamino)androst-5-en-3.beta.-ol and related compoundsuseful as_c__-__ lyase inhibitors |
US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
US5010099A (en) | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
US4966898A (en) | 1989-08-15 | 1990-10-30 | Merrell Dow Pharmaceuticals Inc. | 4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors |
US5395855A (en) | 1990-05-07 | 1995-03-07 | Ciba-Geigy Corporation | Hydrazones |
DE69227986T2 (de) | 1991-03-01 | 1999-06-17 | Electrostatic Technology Inc | Pulverbeschichtungsverfahren zur herstellung von leiterplatten und ähnlichen |
US5145845A (en) | 1991-05-14 | 1992-09-08 | Warner-Lambert Co. | Substituted 2-carboxylindoles having pharmaceutical activity |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
US5457102A (en) | 1994-07-07 | 1995-10-10 | Janssen Pharmaceutica, N.V. | Pyrroloimidazolyl and imidazopyridinyl substituted 1H-benzimidazole derivatives |
JP2742331B2 (ja) | 1992-03-31 | 1998-04-22 | ブリテイツシユ・テクノロジー・グループ・リミテツド | 癌治療に有用な17位置換ステロイド |
TW225528B (es) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
CA2145985C (en) | 1992-10-28 | 2003-09-16 | Napoleone Ferrara | Vascular endothelial cell growth factor antagonists |
DE4332168A1 (de) | 1993-02-22 | 1995-03-23 | Thomae Gmbh Dr K | Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
GB9310635D0 (en) | 1993-05-21 | 1993-07-07 | Glaxo Group Ltd | Chemical compounds |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
JP3916092B2 (ja) | 1993-09-17 | 2007-05-16 | 杏林製薬株式会社 | イミダゾリジノン誘導体とその酸付加塩及び老年性痴呆症の治療薬 |
AU676088B2 (en) | 1993-09-30 | 1997-02-27 | British Technology Group Limited | Synthesis of 17-(3-pyridyl) steroids |
KR960704852A (ko) | 1993-09-30 | 1996-10-09 | 오노다 마사요시 | 아졸 유도체 및 이의 약제학적 조성물 (Azole derivative and pharmaceutical composition thereof) |
WO1996014090A1 (en) | 1994-11-07 | 1996-05-17 | Janssen Pharmaceutica N.V. | Compositions comprising carbazoles and cyclodextrins |
JPH08176111A (ja) | 1994-12-20 | 1996-07-09 | Kyorin Pharmaceut Co Ltd | N,n′−ジ置換エチレンジアミン誘導体及びそれらを用いたn,n′−ジ置換イミダゾリジノン誘導体の製造方法 |
EP2295415A1 (en) | 1995-03-30 | 2011-03-16 | OSI Pharmaceuticals, Inc. | Quinazoline derivatives |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
AU6015796A (en) | 1995-06-14 | 1997-01-15 | Yamanouchi Pharmaceutical Co., Ltd. | Fused imidazole derivatives and medicinal composition thereof |
SI9620103A (sl) | 1995-07-06 | 1998-10-31 | Novartis Ag | Pirolopirimidini in postopki za njihovo pripravo |
WO1997008150A1 (en) | 1995-08-22 | 1997-03-06 | The Du Pont Merck Pharmaceutical Company | Substituted cyclic ureas and derivatives thereof useful as retroviral protease inhibitors |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
PL190489B1 (pl) | 1996-04-12 | 2005-12-30 | Warner Lambert Co | Nieodwracalne inhibitory kinaz tyrozyny, kompozycja farmaceutyczna je zawierająca i ich zastosowanie |
EP0907642B1 (en) | 1996-06-24 | 2005-11-02 | Pfizer Inc. | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases |
WO1998008849A1 (de) | 1996-08-30 | 1998-03-05 | Novartis Aktiengesellschaft | Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens |
CA2264908C (en) | 1996-09-06 | 2006-04-25 | Obducat Ab | Method for anisotropic etching of structures in conducting materials |
DE19638745C2 (de) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
CA2265630A1 (en) | 1996-09-13 | 1998-03-19 | Gerald Mcmahon | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
DE59712968D1 (de) | 1996-11-18 | 2008-10-30 | Biotechnolog Forschung Gmbh | Epothilone E und F |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
DE69823222T2 (de) | 1997-10-02 | 2005-04-14 | Daiichi Pharmaceutical Co., Ltd. | Dihydronaphthalinderivate und verfahren zur herstellung derselben |
GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
JP2002504540A (ja) | 1998-02-25 | 2002-02-12 | スローン−ケッタリング インスティトゥート フォア キャンサー リサーチ | エポチロンの合成、その中間体およびそのアナログ |
ATE293102T1 (de) | 1998-04-23 | 2005-04-15 | Takeda Pharmaceutical | Naphthalene derivate ,ihre herstellung und verwendung |
ATE459616T1 (de) | 1998-08-11 | 2010-03-15 | Novartis Ag | Isochinoline derivate mit angiogenesis-hemmender wirkung |
GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
KR100716272B1 (ko) | 1998-11-20 | 2007-05-09 | 코산 바이오사이언시즈, 인코포레이티드 | 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질 |
DK1140173T4 (da) | 1998-12-22 | 2013-06-10 | Genentech Inc | Vaskulære endothelcellevækstfaktorantagonister og anvendelser deraf |
DE60028740T2 (de) | 1999-03-30 | 2007-05-24 | Novartis Ag | Phthalazinderivate zur behandlung von entzündlichen erkrankungen |
WO2001054694A1 (en) | 2000-01-28 | 2001-08-02 | Bristol-Myers Squibb Company | Tetrahydropyrimidone inhibitors of fatty acid binding protein and method |
AU2001288605A1 (en) | 2000-09-06 | 2002-03-22 | Chugai Seiyaku Kabushiki Kaisha | A traceless solid-phase synthesis of 2-imidazolones |
AR035885A1 (es) | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
US20040198773A1 (en) | 2001-09-26 | 2004-10-07 | Barry Hart | Substituted 3-pyridyl oxazoles as c17,20 lyase inhibitors |
WO2003027101A1 (en) * | 2001-09-26 | 2003-04-03 | Bayer Pharmaceuticals Corporation | Substituted 3-pyridyl pyrroles and 3-pyridyl pyrazoles as c17,20 lyase inhibitors |
GB0200283D0 (en) | 2002-01-08 | 2002-02-20 | Smithkline Beecham Plc | Compounds |
CA2493458A1 (en) | 2002-07-24 | 2004-01-29 | Ptc Therapeutics, Inc. | Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations |
GB0418900D0 (en) | 2004-08-24 | 2004-09-29 | Btg Int Ltd | Novel salt forms |
US20080070867A1 (en) | 2005-01-19 | 2008-03-20 | Metabasis Therapeutics, Inc. | 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases |
CN103349664A (zh) | 2005-03-02 | 2013-10-16 | 马里兰州立大学巴尔的摩分校 | 含甾族的c-17苯并吡咯的组合物 |
WO2006104280A1 (ja) | 2005-03-31 | 2006-10-05 | Takeda Pharmaceutical Company Limited | 糖尿病の予防・治療剤 |
EP2010524A2 (en) | 2006-03-21 | 2009-01-07 | Epix Delaware, Inc. | S1p receptor modulating compounds |
KR20090060306A (ko) | 2006-08-25 | 2009-06-11 | 코우가 바이오테크놀로지, 인크. | 비타민 d 화합물 및 추가 치료제, 및 그를 함유하는 조성물을 투여하는 것을 포함하는, 암을 치료하는 방법 |
WO2008044700A1 (fr) | 2006-10-11 | 2008-04-17 | Takeda Pharmaceutical Company Limited | INHIBITEUR DE LA GSK-3β |
EP2108017A2 (en) | 2007-01-30 | 2009-10-14 | Biogen Idec MA, Inc. | Imidazolone compounds as tgf-beta family type i receptors, alk5 and/or alk4 antagonists |
WO2008154382A1 (en) | 2007-06-06 | 2008-12-18 | University Of Maryland, Baltimore | Hdac inhibitors and hormone targeted drugs for the treatment of cancer |
CN101084881B (zh) | 2007-06-23 | 2012-08-29 | 淮北辉克药业有限公司 | 靶向速释泡腾制剂及其制备方法 |
WO2009078992A1 (en) | 2007-12-17 | 2009-06-25 | Amgen Inc. | Linear tricyclic compounds as p38 kinase inhibitors |
CA2712897A1 (en) | 2008-01-30 | 2009-08-06 | Pharmacopeia, Inc. | Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands |
CL2009001214A1 (es) | 2008-05-19 | 2010-12-31 | Schering Corp | Compuestos derivados de heterociclo, moduladores de serina proteasas composicion fa<rmacaeutica que los comprende; y su uso en el tratamiento de trastornos tromboembolicos |
EP2297133B1 (en) | 2008-06-25 | 2017-09-13 | Forum Pharmaceuticals Inc. | 1, 2 disubstituted heterocyclic compounds |
MX2010014572A (es) | 2008-06-27 | 2011-03-24 | Novartis Ag | Compuestos organicos. |
JP2012505898A (ja) | 2008-10-16 | 2012-03-08 | シェーリング コーポレイション | ピロリジン、ピペリジンおよびピペラジン誘導体ならびにそれらの使用方法 |
WO2010099518A2 (en) | 2009-02-27 | 2010-09-02 | Thesis Chemistry, Llc | Method for manufacture of 2-oxoimidazolidines |
DK2445903T3 (da) | 2009-06-26 | 2014-06-23 | Novartis Ag | 1,3-Disubstituerede imidazolidin-2-on-derivater som CYP17-inhibitorer |
WO2011017534A2 (en) | 2009-08-07 | 2011-02-10 | Tokai Pharmaceuticals, Inc. | Treatment of prostate cancer |
AU2010319697B2 (en) | 2009-11-13 | 2016-05-19 | Tokai Pharmaceuticals, Inc. | Mammalian metabolites of steroids |
WO2011088160A2 (en) | 2010-01-15 | 2011-07-21 | Biomarin Pharmaceutical Inc. | Novel cyp17 inhibitors |
GB201002563D0 (en) | 2010-02-15 | 2010-03-31 | Cambridge Entpr Ltd | Compounds |
WO2012035078A1 (en) | 2010-09-16 | 2012-03-22 | Novartis Ag | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS |
ES2656218T3 (es) | 2011-04-28 | 2018-02-26 | Novartis Ag | Inhibidores de 17 alfa-hidroxilasa/C17,20-liasa |
-
2012
- 2012-04-27 ES ES12718554.4T patent/ES2656218T3/es active Active
- 2012-04-27 EA EA201391586A patent/EA023064B1/ru not_active IP Right Cessation
- 2012-04-27 MX MX2013012577A patent/MX359399B/es active IP Right Grant
- 2012-04-27 US US14/113,718 patent/US9029399B2/en active Active
- 2012-04-27 CN CN201280031400.8A patent/CN103649073B/zh active Active
- 2012-04-27 JP JP2014508135A patent/JP6002210B2/ja active Active
- 2012-04-27 WO PCT/US2012/035583 patent/WO2012149413A1/en active Application Filing
- 2012-04-27 KR KR20137031438A patent/KR20140025492A/ko active IP Right Grant
- 2012-04-27 BR BR112013027395A patent/BR112013027395A2/pt not_active Application Discontinuation
- 2012-04-27 CA CA2834224A patent/CA2834224A1/en not_active Abandoned
- 2012-04-27 AU AU2012249421A patent/AU2012249421B9/en active Active
- 2012-04-27 EP EP12718554.4A patent/EP2702052B1/en active Active
-
2015
- 2015-04-09 US US14/682,504 patent/US9339501B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2014512411A (ja) | 2014-05-22 |
JP6002210B2 (ja) | 2016-10-05 |
CA2834224A1 (en) | 2012-11-01 |
EP2702052B1 (en) | 2017-10-18 |
EP2702052A1 (en) | 2014-03-05 |
AU2012249421A1 (en) | 2013-11-21 |
AU2012249421B2 (en) | 2015-09-24 |
US9029399B2 (en) | 2015-05-12 |
EA023064B1 (ru) | 2016-04-29 |
US20150209356A1 (en) | 2015-07-30 |
WO2012149413A1 (en) | 2012-11-01 |
US9339501B2 (en) | 2016-05-17 |
CN103649073A (zh) | 2014-03-19 |
CN103649073B (zh) | 2016-04-13 |
MX2013012577A (es) | 2014-02-27 |
EA201391586A1 (ru) | 2014-04-30 |
US20140228386A1 (en) | 2014-08-14 |
AU2012249421B9 (en) | 2015-10-22 |
KR20140025492A (ko) | 2014-03-04 |
ES2656218T3 (es) | 2018-02-26 |
BR112013027395A2 (pt) | 2017-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX341456B (es) | Amino-quinolinas como inhibidores de cinasa. | |
MX358376B (es) | Nuevos derivados dihidroquinolina-2-ona. | |
PH12014502733A1 (en) | Neprilysin inhibitors | |
PH12015500260A1 (en) | Neprilysin inhibitors | |
AU2012214029A8 (en) | Rorgammat inhibitors | |
PH12014501179B1 (en) | New bicyclic dihydroisoquinoline-1-one derivatives | |
IN2014MN02598A (es) | ||
EP2566477A4 (en) | AMINO-QUINOLINES AS KINASE INHIBITORS | |
MX2016002794A (es) | Compuestos antiproliferativos. | |
MX2016007861A (es) | Compuestos de ácido dimetilbenzoico. | |
MY186599A (en) | Substituted pyridopyrazines as novel syk inhibitors | |
JO3318B1 (ar) | مثبطات bace | |
EA201492287A1 (ru) | Дейтерированные производные руксолитиниба | |
MY169267A (en) | New aryl-quinoline derivatives | |
MX2012008141A (es) | Compuestos y metodos. | |
PH12015501175A1 (en) | Substituted pyridopyrazines as syk inhibitors | |
IN2014CN04449A (es) | ||
PH12015502032A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
MX2013005819A (es) | Benzoxazepinas como inhibidores de 3-cinasa/objetivo mamífero de rapamicina (pi3k/mtor) metodos de uso y fabricacion. | |
MX359399B (es) | Inhibidores de 17alfa-hidroxilasa/c17-20-liasa. | |
MX2015007309A (es) | Derivado de hidantoina. | |
AU2013314244A8 (en) | Novel inhibitor compounds of phosphodiesterase type 10A | |
MY162945A (en) | Azole derivative | |
MX2013009386A (es) | Nuevos compuestos de azaespirodecanona. | |
MX342311B (es) | Nuevos compuestos de azaespirodecanona como inhibidores de lipasa sensible a hormonas (hsl). |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |